Intrauterine Infusion and Hysteroscopic Injection of Autologous Platelet-Rich Plasma for Patients with a Persistent Thin Endometrium: A Prospective Case-Control Study.
Tzu-Ning YuTsung-Hsien LeeMaw-Sheng LeeYi-Chun ChenChung-I ChenEn-Hui ChengPin-Yao LinChun-Chia HuangChun-I LeePublished in: Journal of clinical medicine (2024)
Objectives : To evaluate the effect of intrauterine infusion and hysteroscopic injection of autologous platelet-rich plasma (PRP) in patients with a persistent thin endometrium (EM) undergoing euploid frozen embryo transfer (EFET) cycles. Methods : This prospective case-control study enrolled 116 infertile women with thin EM (<7 mm) who underwent hormone replacement therapy (HRT) for EFET. These women had experienced at least one previous unsuccessful EFET cycle, which either resulted in the cancellation of the cycle or failure of pregnancy. A total of 55 women received an intrauterine infusion of PRP before FET, 38 received a hysteroscopic injection of PRP, and 23 received standard HRT treatment without PRP (control group). Only euploid embryos were transferred in these cycles. The primary outcomes were the implantation rate (IR) and clinical pregnancy rate (CPR) after EFET. Results : After receiving intrauterine infusion and hysteroscopic injection of PRP, 78.2% and 55.3% of patients, respectively, showed an EM thickness exceeding 7 mm, followed by embryo transfer. The hysteroscopic injection group demonstrated significantly higher IR (52%), a higher trend of CPR (52%), and a higher live birth rate (38%) than the control group (18%, 22%, and 4%). Conclusions : Intrauterine infusion and hysteroscopic injection of autologous PRP may be effective methods to increase EM thickness in HRT cycles. According to our results, both methods could increase EM thickness, while hysteroscopic injection appeared to provide more significant assistance in increasing IR, CPR, and live birth rate after EFET in patients with persistent thin EM.
Keyphrases
- platelet rich plasma
- ultrasound guided
- cardiac arrest
- low dose
- pregnancy outcomes
- replacement therapy
- polycystic ovary syndrome
- cardiopulmonary resuscitation
- end stage renal disease
- type diabetes
- chronic kidney disease
- metabolic syndrome
- preterm birth
- pregnant women
- ejection fraction
- adipose tissue
- insulin resistance
- prognostic factors
- gestational age
- cell therapy
- stem cells
- combination therapy
- mesenchymal stem cells